Natrol launches vitamin supplement
CHATSWORTH, Calif. Natrol on Thursday launched Fish Oil + Vitamin D3, a combination of nutrients for overall health and immunity. The supplement is formulated as a softgel to be taken once daily at an average suggested retail price of $16.99.
The company cited recent scientific studies that have shown vitamin D3 — the vitamin that the body manufactures from sunlight — to be beneficial for aiding overall health, including bone health, immunity support and cellular protection in both men and women, and especially for middle-age and older adults, as the genesis for combining the two ingredients.
Commonly known for their heart health and bone health benefits, fish oil (omega-3 fats) and vitamin D have recently been studied for their cellular activity and abilities to promote breast health, colon health and prostate health, Natrol added. At the cellular level, research shows that omega-3 fats are the building blocks for cellular membranes.
Luckianow joins Greenwood Group
BUFFALO, N.Y. The Greenwood Group on Wednesday announced the addition of Neil Luckianow to its team.
“[Luckianow’s] expertise in trade marketing and sales will be a great asset to our organization and our clients. We’re excited to have him on board,” stated Patrick O’Leary, president of Greenwood Group.
Luckianow has 25 years of experience and is a recognized expert in trade marketing, trade relations and sales management. His achievements include designing retail sales and marketing strategies that reverse market-share slides and help clients bring products successfully from inception to full commercialization, the Greenwood Group stated.
Schering-Plough moves forward on Zegerid switch, responds to FDA complete response letter
SAN DIEGO There is still an opportunity for a second proton-pump inhibitor to join Novartis Consumer Healthcare’s Prevacid 24HR this fall.
Santarus on Tuesday announced that Schering-Plough HealthCare Products has submitted its response to the Food and Drug Administration’s complete response letter issued in January.
Schering-Plough had licensed the OTC switch rights from Santarus for Zegerid, an omeprazole/sodium bicarbonate combination product, in 2006.